Clinical Trials Logo

Filter by:
  • Available  
  • Page [1]
NCT ID: NCT03906331 Available - Breast Cancer Clinical Trials

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Start date: n/a
Phase:
Study type: Expanded Access

Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

NCT ID: NCT03905499 Available - Clinical trials for Pseudoparalysis Due to Massive Rotator Cuff Tear

Robot Assisted Physical Therapy for Pseudoparalysis in Massive Rotator Cuff Tear

Start date: n/a
Phase:
Study type: Expanded Access

The primary objective of this study is to assess the efficacy of a robot assisted therapy in a clinical setting and its potential benefit for patients with rotator cuff tear associated with pseudoparalysis. eighty patients with clinical signs of pseudoparalysis will be recruited through doctors and physical therapists based on eligibility criteria. After completing the baseline assessments, patients will be randomized into the robot-assisted physical therapy intervention or control comparison group. Enrolled patients will conduct a specific trainings program with the MJS Tecnobody (Multi Joint System 614P Tecnobody Srl, IT) three times a week over a period of six weeks. Feasibility assessment will be performed six and twelve weeks after baseline and secondary outcomes (Oxford shoulder score, subjective shoulder value, pain level during activity of daily living, active shoulder flexion and abduction and quality of life EQ-5D-5L) will be assessed at baseline, six and twelve weeks post intervention.

NCT ID: NCT03763604 Available - Clinical trials for Metastatic Breast Cancer

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Start date: n/a
Phase:
Study type: Expanded Access

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.